NGGT
Latest round
- Series B
Last raised
- Jul 2023
Total raised
- $70M
Investors
- 9
About NGGT
Established in 2020 and based in Suzhou, China, NGGT is a biopharmaceutical company that develops genetic drugs and provides corresponding therapeutic services. The company has built a 1000L scale cGMP manufacturing system, and several differentiated R&D pipelines have completed clinical IIT studies or are in the process of registered clinical studies. Dr. Lixin Jiang, the founder of the company, has 25 years of experience in gene therapy and related biopharmaceuticals, and has presided over the national "Gene Vector Platform Technology Development and Industrialization" project. The company focuses on the key technology research of gene drug therapy for viral infections, the development of anti-HIV gene drugs, and the research and development of gene drugs against Hepatitis B virus infection, mainly covering genetic diseases such as blood system, ophthalmology system, and neurological diseases. Its current products include NGGT001, a gene therapy drug targeting retinitis pigmentosa, which received IND approval from the FDA in April 2023, and NGGT002, a gene therapy drug targeting metabolic diseases that is administered through a systemic delivery system, which received Orphan Drug Designation from the FDA in January 2023.
Who invested in NGGT
9 investors across 2 rounds
See all investors in NGGT
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NGGT
Who invested in NGGT?
NGGT has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NGGT raised?
NGGT has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did NGGT last raise money?
NGGT's most recent round on record is a Series B, in Jul 2023.
What does NGGT do?
Established in 2020 and based in Suzhou, China, NGGT is a biopharmaceutical company that develops genetic drugs and provides corresponding therapeutic services.
Where is NGGT headquartered?
NGGT is headquartered in Suzhou, China.
Which VCs invest in companies like NGGT?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at NGGT's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like NGGT? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.